<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01957293</url>
  </required_header>
  <id_info>
    <org_study_id>2013DR2134</org_study_id>
    <nct_id>NCT01957293</nct_id>
  </id_info>
  <brief_title>Influence of Salbutamol on Emotional and Cognitive Functions in Healthy Subjects</brief_title>
  <acronym>Salmon-Basel</acronym>
  <official_title>Influence of Salbutamol on Emotional and Cognitive Functions in Healthy Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Prof. Dominique de Quervain, MD</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Clinical Trial Unit, University Hospital Basel, Switzerland</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Basel</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Aim is to investigate the effect of beta2 adrenergic stimulant salbutamol on emotional and
      cognitive functions in healthy humans.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>October 2013</start_date>
  <completion_date type="Actual">February 2014</completion_date>
  <primary_completion_date type="Actual">January 2014</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change of emotional memory functions under Salbutamol</measure>
    <time_frame>two testing days within 10 days</time_frame>
    <description>memory tests</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change of episodic memory functions under Salbutamol</measure>
    <time_frame>two testing days within10 days</time_frame>
    <description>memory tests</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change of emotional state under salbutamol</measure>
    <time_frame>Two testing days within 10 days</time_frame>
    <description>questionnaires</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>change of attention functions under salbutamol</measure>
    <time_frame>two testing days within 10 days</time_frame>
    <description>attention tests</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">40</enrollment>
  <condition>Memory Functions</condition>
  <arm_group>
    <arm_group_label>Salbutamol</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Sugar Syrup</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Salbutamol</intervention_name>
    <description>single oral administration, 4 mg</description>
    <arm_group_label>Salbutamol</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>single oral administration</description>
    <arm_group_label>Sugar Syrup</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        Healthy, male and female, aged between 18 and 40, BMI be-tween 19 and 27 kg/m2,
        normotensive (BP between 90/60 mmHg and 140/90 mmHg), native or fluent German-speaking,
        caucasian (European ancestry), able and willing to give written informed consent and comply
        with the requirements of the study protocol, willing to donate saliva sample for
        DNA-analysis -

        Exclusion Criteria:

        Acute or chronic psychiatric or somatic disorder, tachycardia at rest (&gt; 100 bpm), known
        hypersensitivity to salbutamol, pathological ECG, pregnancy, breast-feeding, long-term
        medication within last 3 months (oral contraceptives are disregarded) smoking (&gt;3
        cigarettes per day), concurrent participation in another study, participation in one of our
        previous studies using the same memory tests, inability to read and understand the
        participant's information. -
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>40 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Dominique de Quervain, Prof. MD</last_name>
    <role>Study Director</role>
    <affiliation>University of Basel</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Basel, Division of Cognitive neuroscience</name>
      <address>
        <city>Basel</city>
        <zip>4055</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Switzerland</country>
  </location_countries>
  <verification_date>February 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 24, 2013</study_first_submitted>
  <study_first_submitted_qc>September 30, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 8, 2013</study_first_posted>
  <last_update_submitted>December 15, 2014</last_update_submitted>
  <last_update_submitted_qc>December 15, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 16, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>University of Basel</investigator_affiliation>
    <investigator_full_name>Prof. Dominique de Quervain, MD</investigator_full_name>
    <investigator_title>Director of teh Division of Cognitive Neuroscience</investigator_title>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Albuterol</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

